Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 1,432 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Level B Clear all
Recruiting Phase 1 Interventional

A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas

NCT05773040
View directory record Official record
Conditions
Lymphomas, B-cell Lymphomas
Interventions
JV-213, Leukapheresis
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Adenovirus Vaccine for Malaria

NCT00371189
View directory record Official record
Conditions
Plasmodium Falciparum Infection
Interventions
Placebo, Ad35.CS.01 Circumsporozoite Malaria Vaccine
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
2
States / cities
Stanford, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 22, 2014 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Protecting Our Future Generation: Promotion of Protective Sexual Health Practices Among Native American Youth and Young Adults Through an Assets-based Self-care Intervention

NCT03895320
View directory record Official record
Conditions
Sexual Behavior, Unprotected Sex, Gonorrhea, Chlamydia, Trichomonas, Sexually Transmitted Diseases, Adolescent Behavior, Self Evaluation
Interventions
Sexual Health Risk Assessment, Sexual Health Score, Sexual Health Messaging, Water SSB Quiz, Water SSB Score, Water SSB Messaging, STI Screening
Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
14 Years to 26 Years
Enrollment
219 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 23, 2024 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Individualized Piano Instruction (IPI) for Improving Cognition in Breast Cancer Survivors.

NCT05909813
View directory record Official record
Conditions
Breast Cancer, Chemotherapy-Related Cognitive Impairment
Interventions
Individualized Piano Keyboard Instruction
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 3 Interventional

Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)

NCT00065715
View directory record Official record
Conditions
Common Cold
Interventions
Echinacea, Blinded placebo
Dietary Supplement · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
12 Years and older
Enrollment
719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study of mRNA-1020 and mRNA-1030 Seasonal Influenza Vaccines in Healthy Adults

NCT05333289
View directory record Official record
Conditions
Seasonal Influenza
Interventions
mRNA-1030, mRNA-1020, mRNA-1010, Active Comparator
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
572 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
15
States / cities
Phoenix, Arizona • Coral Gables, Florida • Jupiter, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2024 · Synced Oct 21, 2026, 7:14 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours

NCT06833008
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
IPN01195
Drug
Lead sponsor
Ipsen
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
5
States / cities
Grand Rapids, Michigan • Nashville, Tennessee • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional

Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)

NCT00944905
View directory record Official record
Conditions
Renal Cell Carcinoma, Non-hodgkin's Lymphoma
Interventions
MDX-1203
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
5
States / cities
New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated May 22, 2013 · Synced Oct 21, 2026, 7:14 PM EDT
Not yet recruiting Phase 1 Interventional

Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

NCT07725406
View directory record Official record
Conditions
Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
Interventions
Lymphodepleting chemotherapy: Cyclophosphamide, Lymphodepleting chemotherapy: Bendamustine, Lymphodepleting chemotherapy: Fludarabine, Lisocabtagene Maraleucel, Axicabtagene Ciloleucel, Ciltacabtagene Autoleucel, Low-Dose Total Body Irradiation
Drug · Other · Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 4 Interventional Results available

Study of Insulin Lispro in Participants With Inadequately Controlled Type 2 Diabetes

NCT01215955
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin lispro, Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
33
States / cities
Phoenix, Arizona • Concord, California • Fresno, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2014 · Synced Oct 21, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional

Study of REGN1193 in Patients With Type 2 Diabetes Mellitus

NCT02284425
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
REGN1193, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
25 Years to 70 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
3
States / cities
Miami, Florida • Atlanta, Georgia • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 21, 2026, 7:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

MIRA CONNECT Study

NCT06802263
View directory record Official record
Conditions
Pregnancy of Unknown Location (PUL)
Interventions
at-home quantitative urine b-hCG test
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 16, 2025 · Synced Oct 21, 2026, 7:14 PM EDT
Active, not recruiting Phase 1 Interventional

PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy

NCT04837547
View directory record Official record
Conditions
Neuroblastoma, Diffuse Intrinsic Pontine Glioma
Interventions
Tumor-specific ex vivo expanded autologous lymphocyte transfer (TTRNA-xALT)
Biological
Lead sponsor
University of Florida
Other
Eligibility
1 Year to 30 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
3
States / cities
Gainesville, Florida • Charlotte, North Carolina • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Recruiting Phase 1 Interventional

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

NCT07600749
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
MK-4884
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
2
States / cities
St Louis, Missouri • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Not applicable Interventional

Dietary Oxysterols and β-Cell Function Among African Americans

NCT05072587
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Plant-based diet with no oxysterols, Standard ADA Diet (SADA)
Behavioral
Lead sponsor
Morehouse School of Medicine
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Withdrawn Phase 1Phase 2 Interventional Accepts healthy volunteers

MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly

NCT01623232
View directory record Official record
Conditions
Influenza Vaccines, Aged
Interventions
MAS-1 adjuvant and influenza HA antigen, standard dose, inactivated trivalent influenza vaccine (TIV)
Biological
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
65 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
4
States / cities
Palo Alto, California • Iowa City, Iowa • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2012 · Synced Oct 21, 2026, 7:14 PM EDT
Terminated Phase 1 Interventional

Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin Lymphoma

NCT01609816
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Multiple, Mycosis Fungoides, Hodgkin's Lymphoma, Multiple Myeloma
Interventions
Dasatinib
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 16, 2020 · Synced Oct 21, 2026, 7:14 PM EDT
Withdrawn Not applicable Interventional

A Study to Evaluate the Role of Alternative Medicine in Difficult to Treat GERD Patients

NCT00591877
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Acupuncture, Sham Acupuncture, Yoga
Procedure · Other
Lead sponsor
Midwest Biomedical Research
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 26, 2012 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Safety, Tolerability, Pharmacokinetics, Food Effect and Pharmacodynamics of Single and Multiple Ascending Doses of P7435 in Healthy, Overweight or Obese Subjects

NCT01910571
View directory record Official record
Conditions
Healthy
Interventions
P7435, Placebo
Drug · Other
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Nov 26, 2014 · Synced Oct 21, 2026, 7:14 PM EDT
Not yet recruiting Not applicable Interventional

Self-Managed Exercise in Chronic Stroke

NCT07799987
View directory record Official record
Conditions
Stroke
Interventions
Exercise, Behavioral Management Program
Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 89 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

NCT04065399
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Mixed Lineage Acute Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia of Ambiguous Lineage
Interventions
revumenib, cobicistat
Drug
Lead sponsor
Syndax Pharmaceuticals
Industry
Eligibility
30 Days and older
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
22
States / cities
Duarte, California • Los Angeles, California • Palo Alto, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Safety and Efficacy of Tegavivint in Patients With Metastatic Colorectal Carcinoma

NCT07463599
View directory record Official record
Conditions
Metastatic Colorectal Carcinoma (mCRC), Colorectal Cancer (CRC), Adenomatous Polyposis Coli (APC) Gene Mutation, Catenin Beta-1 (CTNNB1) Gene Mutation
Interventions
Tegavivint
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Solius UV Light Source in Improving Serum Levels of 25-hydroxyvitamin D

NCT04865432
View directory record Official record
Conditions
Vitamin D Deficiency, Vitamin D Insufficiency
Interventions
UVB treatment
Device
Lead sponsor
Boston University
Other
Eligibility
22 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 23, 2022 · Synced Oct 21, 2026, 7:14 PM EDT
Completed Phase 1 Interventional Results available

Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

NCT03742258
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Interventions
Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone, Rituximab, Spleen Tyrosine Kinase Inhibitor TAK-659, Vincristine Sulfate
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
2
States / cities
Chicago, Illinois • Lake Forest, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 21, 2026, 7:14 PM EDT